Who Exports Cisplatin from India — 233 Suppliers Behind a $12.8M Market
India's cisplatin export market is supplied by 233 active exporters who collectively shipped $12.8M across 1,701 shipments. FRESENIUS KABI ONCOLOGY LIMITED leads with a 21.5% market share, followed by VENUS REMEDIES LIMITED and INTAS PHARMACEUTICALS LIMITED. The top 5 suppliers together control 61.9% of total export value, reflecting a concentrated market structure.
Top Cisplatin Exporters from India — Ranked by Export Value
FRESENIUS KABI ONCOLOGY LIMITED is the leading cisplatin exporter from India, holding a 21.5% share of the $12.8M market across 1,701 shipments from 233 exporters. The top 5 suppliers — FRESENIUS KABI ONCOLOGY LIMITED, VENUS REMEDIES LIMITED, INTAS PHARMACEUTICALS LIMITED, NV REMEDIES PRIVATE LIMITED, MYLAN LABORATORIES LIMITED — collectively control 61.9% of total export value, indicating a moderately concentrated market. Individual shares are: FRESENIUS KABI ONCOLOGY LIMITED (21.5%), VENUS REMEDIES LIMITED (12.9%), INTAS PHARMACEUTICALS LIMITED (11.3%), NV REMEDIES PRIVATE LIMITED (10.1%), MYLAN LABORATORIES LIMITED (6.0%).
Top Cisplatin Exporters from India
Ranked by export value · 233 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | FRESENIUS KABI ONCOLOGY LIMITED CISPLATIN INJ 1 MG/ML 100 MLKEMOPLAT BP INJ. 50MG/50MLKEMOPLAT BP INJ. 50MG/50ML V | $2.8M | 8 | 21.5% |
| 2 | VENUS REMEDIES LIMITED CISPLATIN INJECTION BP 50 MG/100 ML E.CISPLATIN INJECTION BP 50MG 50MLCISPLATIN INJECTION BPEACH | $1.7M | 22 | 12.9% |
| 3 | INTAS PHARMACEUTICALS LIMITED CISPLATIN INJ 1 MG/ML 100 MLCISPLATIN INJECTION 100MG X 1 100MLCISPLATIN INJECTION 100MG/100ML | $1.5M | 13 | 11.3% |
| 4 | NV REMEDIES PRIVATE LIMITED CISPLATIN VENUS PHARMA 100MG/100ML | $1.3M | 1 | 10.1% |
| 5 | MYLAN LABORATORIES LIMITED CISPLATIN 1MG/ML 100ML P1 ACO-FRANCECISPLATIN 1MG/ML 100ML P1 (ACO-FRANCECISPLATIN VIATRIS 1MG 50ML 1S VIA FRANCE TAX VAL 4080811.48 | $775.1K | 1 | 6.0% |
| 6 | GLAND PHARMA LIMITED CISPLATIN INJ 1 MG/ML 100 MLCISPLATIN INJECTION 100MG X 1 100MLCISPLATIN INJECTION 100MG/100ML | $530.1K | 1 | 4.1% |
| 7 | NAPROD LIFE SCIENCES PRIVATE LIMITED PHARMA DRUG&MED:PLATIN-CISPLATIN 1MG/ML,PLATOL 50 MG 100 ML CISPLATIN INJECTION BP 50MG 100 MLCISTEEN CISPLATIN INJECTION BP 50MG/50ML | $507.6K | 8 | 3.9% |
| 8 | UNITED BIOTECH PRIVATE LIMITED | $489.4K | 14 | 3.8% |
| 9 | INTAS PHARMACEUTICALS LTD CISPLATIN INJ 1 MG/ML 100 MLCISPLATIN INJECTION 100MG X 1 100MLCISPLATIN INJECTION 100MG/100ML | $268.6K | 9 | 2.1% |
| 10 | SP ACCURE LABS PRIVATE LIMITED CISPLATIN INJ 1 MG/ML 100 MLCISPLATIN INJECTION 100MG X 1 100MLCISPLATIN INJECTION 100MG/100ML | $233.8K | 9 | 1.8% |
| 11 | MEDORBIS TRADE LLP CISPLATIN INJECTION BP 50 MG/100 ML E.CISPLATIN INJECTION BP 50MG 50MLCISPLATIN INJECTION BP 50MG/50ML | $208.8K | 2 | 1.6% |
| 12 | BETA DRUGS LIMITED PLATOL 50 MG 100 ML CISPLATIN INJECTION BP 50MG 100 MLPLATOL CISPLATIN INJECTION BP 50 MG /100 ML | $180.9K | 12 | 1.4% |
| 13 | VHB MEDI SCIENCES LIMITED | $174.3K | 6 | 1.4% |
| 14 | PRIME PHARMACEUTICALS PRIVATE LIMITED KEMOPLAT CISPLATIN INJ 50MG 50ML VIALKEMOPLAT INJ. 50MG/50ML VIALPLATOL 50MG (CISPLATIN INJEC | $151.4K | 1 | 1.2% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Cisplatin exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Fresenius Kabi Oncology Limited | Warning Letter (December | Yes | Yes | Not verified | Received FDA warning letters in December 2017 for CGMP violations at Kalyani and |
| Venus Remedies Limited | Not Listed | Yes | Yes | Not verified | Secured EU GMP renewal from Infarmed, Portugal, in January 2025 for cephalospori |
| Gland Pharma Limited | Approved | Yes | Yes | Not verified | Manufacturing facilities approved by FDA, WHO, and EU authorities. |
| Intas Pharmaceuticals Limited | Approved | Yes | Yes | Not verified | Holds approvals from FDA, WHO, and EU GMP certifications. |
| Mylan Laboratories Limited | Approved | Yes | Yes | Not verified | Facilities approved by FDA, WHO, and EU authorities. |
| Naprod Life Sciences Private Limited | Not Listed | Yes | Yes | Not verified | Holds WHO and EU GMP certifications for oncology products. |
| United Biotech Private Limited | Not Listed | Yes | Yes | Not verified | Certified by WHO and EU GMP authorities for pharmaceutical manufacturing. |
| SP Accure Labs Private Limited | Not Listed | Yes | Yes | Not verified | Holds WHO and EU GMP certifications for pharmaceutical products. |
TransData Nexus reviewed the regulatory standing of 8 leading Cisplatin exporters from India. 3 hold US FDA facility approvals, 8 maintain WHO-GMP certification, and 8 are EU GMP compliant. 1 supplier has received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Cisplatin sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," contributes to more than 40% of the country's bulk drug production. The city hosts numerous bulk drug manufacturers, including Vasudha Pharma Chem Ltd, which specializes in active pharmaceutical ingredients (APIs) and intermediates. The presence of esteemed research institutions like the National Institute of Pharmaceutical Education and Research (NIPER) Hyderabad further strengthens the region's pharmaceutical capabilities. NIPER Hyderabad aims to be a principal source of professional manpower in the field, enhancing the Indian pharmaceutical industry's capacity to produce quality products at affordable prices.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its pharmaceutical formulations industry. Vadodara, in particular, is home to major pharmaceutical companies like Alembic Pharmaceuticals, which manufactures and markets a wide range of pharmaceutical products, including APIs and formulations. The region's robust infrastructure and skilled workforce make it a pivotal hub for pharmaceutical formulations in India.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for India's pharmaceutical industry. Mumbai's strategic location and well-developed port facilities facilitate efficient international distribution of pharmaceutical products. The region's proximity to major shipping routes and established logistics networks make it an ideal hub for exporting pharmaceuticals to global markets.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing zone, primarily due to favorable tax incentives offered by the government. These incentives have attracted numerous pharmaceutical companies to set up manufacturing units in the area, contributing to its rapid industrial growth.
5Sourcing Recommendations
- Leverage Hyderabad's API Production: Given Hyderabad's dominance in bulk drug manufacturing, sourcing Cisplatin APIs from this region can ensure a steady and reliable supply.
- Utilize Gujarat's Formulation Expertise: Engaging with manufacturers in the Ahmedabad-Vadodara corridor can provide access to high-quality Cisplatin formulations, benefiting from the region's established expertise.
- Optimize Export Logistics via Mumbai: Utilizing the Mumbai-Thane-Raigad region's export infrastructure can enhance the efficiency of international distribution channels for Cisplatin products.
- Consider Cost Benefits in Baddi-Nalagarh: Exploring manufacturing partnerships in the Baddi-Nalagarh region can offer cost advantages due to the area's tax incentives, potentially reducing overall production expenses.
By strategically engaging with these key pharmaceutical clusters, companies can optimize their supply chain for Cisplatin, ensuring quality production and efficient distribution to meet global demand.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Cisplatin exporters from India
Intas Pharmaceuticals Limited — Intas' Accord Plasma acquires Prothya Biosolutions
Accord Plasma, a subsidiary of Intas Pharmaceuticals, completed the acquisition of Prothya Biosolutions Belgium BV and its subsidiaries. This acquisition adds Prothya’s European plasma fractionation facilities and collection network, including operations in Amsterdam, Brussels, and Hungary, to Accord’s global plasma manufacturing footprint, expanding production and access to plasma-derived medicines. - IMPACT: This acquisition enhances Intas Pharmaceuticals' manufacturing capabilities, potentially increasing their capacity for Cisplatin production and export.
Impact: This acquisition enhances Intas Pharmaceuticals' manufacturing capabilities, potentially increasing their capacity for Cisplatin production and export.
Mylan Laboratories Limited — Viatris acquires Aculys Pharma for CNS assets
Viatris Inc., the parent company of Mylan Laboratories Limited, acquired clinical-stage Aculys Pharma, Inc., obtaining exclusive development and commercialization rights in Japan for pitolisant and rights in Japan and select Asia-Pacific markets for Spydia (diazepam) nasal spray. - IMPACT: While this acquisition focuses on central nervous system assets, it may allow Mylan Laboratories to reallocate resources towards enhancing their oncology portfolio, including Cisplatin exports.
Impact: While this acquisition focuses on central nervous system assets, it may allow Mylan Laboratories to reallocate resources towards enhancing their oncology portfolio, including Cisplatin exports.
Mylan Laboratories Limited — Mylan acquires Famy Care's female health business
Mylan Laboratories Limited acquired the female health care businesses from Famy Care Ltd. for $750 million in cash, plus additional contingent payments of up to $50 million. This acquisition builds on Mylan's existing partnerships with Famy Care in North America, Europe, and Australia, providing Mylan with an enhanced and vertically integrated platform to accelerate growth in women's health care. - IMPACT: This strategic acquisition may enable Mylan Laboratories to strengthen its overall pharmaceutical portfolio, potentially impacting its oncology segment and Cisplatin export capabilities.
Impact: This strategic acquisition may enable Mylan Laboratories to strengthen its overall pharmaceutical portfolio, potentially impacting its oncology segment and Cisplatin export capabilities.
Common Questions — Cisplatin Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which cisplatin supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, FRESENIUS KABI ONCOLOGY LIMITED leads with 60 recorded shipments worth $2.8M. VENUS REMEDIES LIMITED (121 shipments) and INTAS PHARMACEUTICALS LIMITED (73 shipments) are also established high-volume exporters.
Q How many cisplatin manufacturers are there in India?
India has 233 active cisplatin exporters with a combined export market of $12.8M across 1,701 shipments to 130 countries. The top 5 suppliers hold 61.9% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for cisplatin from India?
Average FOB unit price: $4.29 per unit, ranging from $0.01 to $525.99. Average shipment value: $7.6K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 233 verified Indian exporters of Cisplatin ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 1,701 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 130 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1,701 Verified Shipments
233 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists